Transmedics Group, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
TransMedics Group reports significant revenue and net income growth for Q3 and the first nine months of 2025, driven by its OCS and NOP programs.
NASDAQ
TransMedics Group, a medical technology company, announced significantly increased revenue and net income for the second quarter and first half of 2025, driven by robust adoption of its Organ Care System and National OCS Program, alongside plans for international manufacturing expansion.
NASDAQ
10-Q: TransMedics Group Reports Strong Q1 2025 Results, Revenue Jumps 48% Amidst Growing OCS Adoption
TransMedics Group's Q1 2025 revenue surged by 48% year-over-year, driven by increased adoption of its Organ Care System (OCS) and National OCS Program (NOP).
NASDAQ
TransMedics Group's Q3 2024 results show significant revenue growth and a shift to profitability, driven by increased adoption of their Organ Care System (OCS) and National OCS Program (NOP).
NASDAQ
TransMedics Group's Q2 2024 results show significant revenue growth and a shift to profitability, driven by increased adoption of their Organ Care System (OCS) and expansion of their National OCS Program (NOP).
NASDAQ
TransMedics Group's first quarter of 2024 saw a significant increase in revenue and a shift to profitability, driven by the adoption of their Organ Care System (OCS) technology.